References:
1. Schlag AK, Aday J, Salam I, et al. Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. J Psychopharmacol 2022; 36 (3): 258–272.
2. Nutt D, Spriggs M, Erritzoe D. Psychedelics therapeutics: what we know, what we think, and what we need to research. Neuropharmacology 2023; 223: 109257.
3. Goodwin GM, Aaronson ST, Alvarez O, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med 2022; 387 (18): 1637–1648.
4. Raison CL, Sanacora G, Woolley J, et al. Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. JAMA 2023; 330 (9): 843–853.
5. Yehuda R, Lehrner A. Psychedelic Therapy-A New Paradigm of Care for Mental Health. JAMA 2023; 330 (9): 813–814.
6. Guideline on clinical investigation of medicinal products in the treatment of depression EMA/CHMP/185423/2010, Rev.3. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf. Accessed 11 October 2023.
7. Nichols DE. Psychedelics. Pharmacol Rev 2016; 68 (2): 264–355.
